XOMAO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health...

Stats
Šios dienos apimtis	46.00
Vidutinė apimtis	2 808.00
Rinkos kapitalizacija	291.81M
EPS	$-0.480 ( 2023-09-29 )
Last Dividend	$0.523 ( 2023-10-04 )
Next Dividend	$0 ( N/A )
P/E	25.07
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Hughes Owen	Buy	275 000	Performance Stock Units
2023-10-03	Sitko Bradley	Buy	250	Common Stock
2023-10-02	Sitko Bradley	Buy	1 500	Common Stock
2023-10-02	Hughes Owen	Buy	1 000	Common Stock
2023-09-26	Hughes Owen	Buy	2 499	Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 1 979 429 \| Sell: 840 426

XOMA Corporation Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RNEM	0.94
NWFL	0.937
IDLB	0.936
PIE	0.936
RFDI	0.936
VIGI	0.935
UCL	0.935
RNDM	0.932
TACT	0.932
VXUS	0.93

10 Labiausiai neigiamai susiję koreliacijos
IMRX	-0.941
LUMO	-0.936
STRC	-0.929
LYRA	-0.926
ONCS	-0.924
ANTE	-0.919
WISA	-0.918
NUWE	-0.917
AFMD	-0.916
ODT	-0.914

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

XOMA Corporation Finansinės ataskaitos

Annual	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2022
Pajamos:	$6.03M
Bruto pelnas:	$5.93M (98.39 %)
EPS:	$-1.500

FY	2021
Pajamos:	$38.16M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

XOMA Corporation Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.523 (N/A)	$0 (N/A)	$0.523 (N/A)	$1.047 (N/A)	$0 (N/A)	$0.523 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XOMA Corporation Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.558	2021-07-01
Last Dividend	$0.523	2023-10-04
Next Dividend	$0	N/A
Payout Date	2023-10-16
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$5.27	--
Avg. Dividend % Per Year	4.67%	--
Score	3.47	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-25)

$0.533 Estimate 19.17 %

Dividend Stability

0.51 Average

Dividend Score

3.47

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2021	$1.081	4.38%
2022	$2.09	8.11%
2023	$2.09	8.70%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-10.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.208	1.200	-6.93	-8.32	[0 - 0.3]
returnOnEquityTTM	-0.465	1.500	-6.28	-9.42	[0.1 - 1]
payoutRatioTTM	-0.112	-1.000	-1.123	1.123	[0 - 1]
currentRatioTTM	8.68	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.87	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.530	-1.500	1.171	-1.757	[0 - 0.6]
interestCoverageTTM	-130.17	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.582	2.00	-0.527	-1.055	[0 - 30]
freeCashFlowPerShareTTM	-2.86	2.00	-1.430	-2.86	[0 - 20]
debtEquityRatioTTM	1.399	-1.500	4.40	-6.61	[0 - 2.5]
grossProfitMarginTTM	0.811	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-5.80	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.146	1.000	-1.924	-1.924	[0.2 - 2]
assetTurnoverTTM	0.0203	0.800	-3.20	-2.56	[0.5 - 2]
Total Score				-1.689

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-6.08	1.000	-0.715	0	[1 - 100]
returnOnEquityTTM	-0.465	2.50	-4.04	-9.42	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.86	2.00	-0.953	-2.86	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.582	2.00	-0.527	-1.055	[0 - 30]
payoutRatioTTM	-0.112	1.500	-1.123	1.123	[0 - 1]
pegRatioTTM	-0.119	1.500	-4.13	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.82	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.16

XOMA Corporation

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.